摘要
目的:观察依达拉奉右莰醇联合替罗非班治疗急性脑梗死(ACI)患者的效果。方法:回顾性分析2020年12月至2023年12月该院收治的62例ACI患者的临床资料,根据治疗方法不同将其分为对照组和研究组各31例。两组均接受溶栓治疗,在此基础上,对照组给予替罗非班治疗,研究组在对照组基础上联合依达拉奉右莰醇治疗。比较两组临床疗效,治疗前后功能独立性[功能独立性评定量表(FIM)]评分、梗死面积、大脑中动脉平均血流速度(Vm)和搏动指数(PI)、炎性因子[肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]水平,以及不良反应发生率。结果:研究组治疗总有效率为93.55%,高于对照组的70.97%,差异有统计学意义(P<0.05);治疗后,两组FIM评分均高于治疗前,且研究组高于对照组,两组梗死面积均小于治疗前,且研究组小于对照组,差异有统计学意义(P<0.05);治疗后,两组大脑中动脉Vm水平均高于治疗前,且研究组高于对照组,两组大脑中动脉PI水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组hs-CRP、TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意(P>0.05)。结论:依达拉奉右莰醇联合替罗非班治疗ACI患者,可提高临床疗效,改善大脑中动脉血液循环,减轻神经损伤和炎症反应,提升功能独立性,效果优于单纯替罗非班治疗。
Objective:To observe effects of Edaravone and Dexborneol combined with Tirofiban in treatment of patients with acute cerebral infarction(ACI).Methods:The clinical data of 62 patients with ACI admitted to this hospital from December 2020 to December 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,31 cases in each group.Both groups received thrombolytic therapy.On this basis,the control group was treated with Tirofiban,while the study group was treated with Edaravone and Dexborneol on the basis of that of the control group.The clinical efficacy,the functional independence[functional independence measure(FIM)]score,the infarct size,the mean blood flow velocity(Vm)and pulsatility index(PI)of middle cerebral artery,the levels of inflammatory factors[tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 93.55%,which was higher than 70.97%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the FIM scores of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the infarct area of the two groups was smaller than that before the treatment,and that in the study group was smaller than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the Vm levels of middle cerebral artery in both groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the PI levels of middle cerebral artery in both groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of hs-CRP and TNF-αin the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Edaravone and Dexborneol combined with Tirofiban in the treatment of the ACI patients can improve the clinical efficacy,improve the blood circulation of middle cerebral artery,reduce the nerve injury and the inflammatory reaction,and improve the functional independence.Moreover,it is superior to simple Tirofiban treatment.
作者
胡奇华
HU Qihua(Second Department of Neurology of Shangshui County People’s Hospital,Zhoukou 466100 Henan,China)
出处
《中国民康医学》
2025年第4期23-26,共4页
Medical Journal of Chinese People’s Health
关键词
依达拉奉右莰醇
替罗非班
急性脑梗死
脑血流动力学
神经功能
Edaravone and Dexborneol
Tirofiban
Acute cerebral infarction
Cerebral hemodynamics
Neurological function
作者简介
胡奇华(1978.11-),男,汉族,河南商水人,本科,副主任医师,研究方向为神经内科神经介入治疗。
